Analysts should understand how a monograph, together with the associated general notices and general chapters, relate to their responsibilities under good manufacturing practices.
The title of this article is deliberatively provocative. Pharmacopoeias contain the legal standards for the quality of medicines with monographs for active ingredients, excipients, and finished products. Analysts should understand how a monograph, together with the associated general notices and general chapters, relates to their responsibilities under good manufacturing practices for ensuring data integrity. However, many pharmacopeial tests therein involve classical chemical analysis (e.g., color, appearance, titration) and rely on an analyst’s observation with little, if any, documented evidence for review. Hence, do pharmacopoeias inadvertently facilitate data integrity violations?
In this article the authors look at the following topics:
Read this article in BioPharm International’s Regulatory Sourcebook October 2020 eBook.
C. Burgess is managing director of Burgess Analytical Consultancy Limited and is the writer of the Statistical Solutions column in Pharmaceutical Technology. R.D. McDowall is director of R D McDowall Limited and is the author of Questions of Quality and Focus on Quality columns in LC-GC Europe and Spectroscopy, respectively.
BioPharm International
eBook: Regulatory Sourcebook, October 2020
October 2020
Pages: 18–27
When referring to this article, please cite it as C. Burgess and R.D. McDowall, “Do Pharmacopoeias Inadvertently Facilitate Data Integrity Violations?" BioPharm International Regulatory Sourcebook (October 2020).
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.